McLeod D T, Calverley P M, Millar J W, Horne N W
Thorax. 1985 Jul;40(7):515-8. doi: 10.1136/thx.40.7.515.
The outcome of drug induced pleurodesis has been evaluated in a non-randomised retrospective study of 67 patients with recurrent malignant pleural effusions treated during 1976-83. Fourteen died within 30 days of treatment. Of the remaining 53 patients, 26 studied during 1976-80 were treated with intrapleural mustine hydrochloride, while 27 studied during 1978-83 were treated with intrapleural Corynebacterium parvum. There was no significant difference between the groups in age, sex, or tumour type, most tumours being secondary to bronchial neoplasms. Corynebacterium parvum successfully prevented reaccumulation of the effusion in 24 (92%) patients, while mustine was effective in only 17 (65%) (p less than 0.05). Data on survival were obtained on 47 cases where a single agent was used to induce pleurodesis. In 25 patients treated with C parvum the mean survival was 251 (range 31-1143) days, compared with 119 (range 31-380) days for the 22 patients in whom mustine was used. Survival of the C parvum group was significantly greater (p less than 0.01). The difference was principally due to the greater number of long term survivors in the C parvum group, nine of this group living for more than 180 days (mean 574, range 180-1143 days) compared with only four such survivors in the mustine group (mean 263, range 193-380 days). This study confirms our initial impression that C parvum is highly effective in controlling recurrent malignant pleural effusions. The finding of unexpected long term survivors with C parvum treatment suggests that this treatment may have an additional effect on the progression of disease, a finding that merits further investigation.
在一项对1976年至1983年间接受治疗的67例复发性恶性胸腔积液患者进行的非随机回顾性研究中,评估了药物诱导胸膜固定术的结果。14例患者在治疗后30天内死亡。在其余53例患者中,1976年至1980年间研究的26例患者接受了胸腔内注射盐酸氮芥治疗,而1978年至1983年间研究的27例患者接受了胸腔内注射短小棒状杆菌治疗。两组在年龄、性别或肿瘤类型方面无显著差异,大多数肿瘤为支气管肿瘤继发。短小棒状杆菌成功预防了24例(92%)患者胸腔积液的再次积聚,而氮芥仅对17例(65%)有效(p<0.05)。在47例使用单一药物诱导胸膜固定术的病例中获得了生存数据。接受短小棒状杆菌治疗的25例患者的平均生存期为251天(范围31 - 1143天),而使用氮芥的22例患者的平均生存期为119天(范围31 - 380天)。短小棒状杆菌组的生存期显著更长(p<0.01)。这种差异主要是由于短小棒状杆菌组长期存活者数量更多,该组中有9例存活超过180天(平均574天,范围180 - 1143天),而氮芥组只有4例此类存活者(平均263天,范围193 - 380天)。这项研究证实了我们最初的印象,即短小棒状杆菌在控制复发性恶性胸腔积液方面非常有效。短小棒状杆菌治疗出现意外的长期存活者这一发现表明,这种治疗可能对疾病进展有额外影响,这一发现值得进一步研究。